Tradestie Institutional Equity Comparison Engine
RAPT vs CELC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RAPT Overall Edge
RAPT Captures Institutional Edge (2โ0 Pillars ยท 4โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to RAPT Therapeutics, Inc. Common Stock (RAPT) driven by superior Momentum & Technical, Options & Structure. Fundamentally, RAPT trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus CELC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RAPT sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against CELC sits in BREAKDOWN (30th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
RAPT N/M vs CELC N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner
RAPT
1Y +480.2% vs -28.7% ยท 52W Pos 100% vs 8%
Options & Structure Winner
RAPT
UNCLASSIFIED (<1st %ile IV) vs BREAKDOWN (30th %ile IV)
RAPT
NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap
$1.7B
1M Return
+0.68%
1Y Return
+480.2%
Forward P/E
N/M
Unified AI Score
52.4 / 100
HOLD
Tech 40.0
Fund 46.0
Flow 61.0
Mom 40.0
CELC
NASDAQ
Celcuity Inc. Common Stock
Services-Medical Laboratories
$61.31
-4.75% 1D
Market Cap
$3.2B
1M Return
+8.36%
1Y Return
-28.71%
Forward P/E
N/M
Unified AI Score
39.7 / 100
SELL
Tech 25.0
Fund 43.0
Flow 59.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
RAPT +480.2%
CELC -28.71%
Spread: +85.1 pp (RAPT Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
RAPT TTM Op. Margin: 0.0%
CELC TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPT vs CELC. Trailing 12-month operating profitability (RAPT 0.0% vs CELC 0.0%) and valuation multiples (RAPT N/M vs CELC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RAPT | CELC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.7B | $3.2B | Larger Scale | CELC |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +0.0% | Higher Growth | CELC |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -85.4% | -1192.9% | Higher ROE | RAPT |
| 52-Week Range Position Momentum | 100% ($1โ$58) | 8% ($54โ$151) | Stronger Trend | RAPT |
| Beta / 30D Volatility Risk Regime | -0.02ฮฒ ยท 2% Vol | 1.28ฮฒ ยท 60% Vol | Lower Realized Risk | RAPT |
| Unified Institutional Score Composite Signal | 52.4 / 100 (HOLD) | 39.7 / 100 (SELL) | Higher Composite | RAPT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full RAPT vs CELC Buy Guide
RAPT
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
CELC
BREAKDOWN
136d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
30th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither RAPT nor CELC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.